This article is for informational and educational purposes only and does not constitute medical advice. Cartalax is supplied by Wholesale Peps as lyophilized research-grade material for in vitro laboratory use only and is not approved by the FDA for human or veterinary use.
Cartalax is a synthetic tripeptide with the sequence Ala-Glu-Asp (AED) and a molecular weight of approximately 333 Da. It belongs to the peptide bioregulator class developed by the research group of Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology — the same group responsible for Epitalon (Ala-Glu-Asp-Gly), Pinealon (Glu-Asp-Arg), and a series of other tissue-targeted short synthetic peptides. Cartalax was developed from research into cartilage-derived peptide fractions and is proposed to modulate gene expression in chondrocytes, the primary cell type responsible for cartilage extracellular matrix synthesis and maintenance. In vitro and animal model studies, conducted predominantly by the originating research group, have examined associations between Cartalax and chondrocyte activity parameters. The published evidence base specific to Cartalax appears to be among the most limited within the peptide bioregulator class, with most available research originating from a single laboratory and published in Russian-language or limited-circulation journals. No peer-reviewed randomized controlled trial evaluating Cartalax in human subjects has been identified as of the review date.
1. Background
1.1 Peptide Bioregulators — The Khavinson Framework
The peptide bioregulator concept was developed in the Soviet Union and subsequently Russia beginning in the 1970s by Vladimir Khavinson and colleagues at the Institute of Bioregulation and Gerontology in St. Petersburg. The foundational hypothesis holds that short peptides — typically 2–4 amino acids in length — derived from or modeled on organ-specific tissue extracts can regulate gene expression in a tissue-targeted manner, with proposed applications in aging biology and age-related disease. The proposed mechanism involves direct interaction of these short peptides with DNA regulatory elements such as gene promoter sequences, influencing transcription of genes relevant to the targeted tissue type [3].
The class includes a range of named compounds, each proposed to target a specific tissue: Epitalon (Ala-Glu-Asp-Gly) for the pineal gland and related neuroendocrine function, Pinealon (Glu-Asp-Arg) for pineal and neuroprotective applications, Vilon (Lys-Glu) for immune regulation, and Cartalax (Ala-Glu-Asp) for cartilage and connective tissue. The biological basis for tissue-specificity — how a tripeptide administered systemically would preferentially regulate gene expression in cartilage rather than other tissues — has not been independently established through mechanistic research [1].
1.2 Articular Cartilage and Chondrocyte Biology
Articular cartilage is a specialized avascular connective tissue that lines the articulating surfaces of synovial joints, providing a low-friction, load-bearing interface. Its extracellular matrix (ECM) is composed primarily of type II collagen — which provides tensile strength and structural framework — and aggrecan, a large proteoglycan that confers compressive resistance through its capacity to retain water [4]. Chondrocytes, the sole resident cell type of cartilage, are responsible for synthesizing and maintaining this matrix.
Cartilage has limited intrinsic repair capacity due to its avascularity and the low mitotic activity of mature chondrocytes. With aging, chondrocyte anabolic activity declines, catabolic activity increases, and matrix composition shifts — changes associated with progressive structural deterioration in conditions such as osteoarthritis. This limited regenerative biology has motivated substantial research interest in approaches that might support chondrocyte anabolic function or protect cartilage matrix integrity [5].
1.3 Development of Cartalax and Structural Context
Cartalax was developed by the Khavinson group using an approach consistent with the broader bioregulator program: isolation and characterization of peptide fractions from bovine cartilage tissue, followed by synthesis and characterization of short peptides representing proposed bioactive sequences. The AED tripeptide sequence was identified as a candidate cartilage bioregulator through this process. Cartalax was subsequently studied in cell-based and animal model systems by the originating group.
A notable structural relationship exists between Cartalax (Ala-Glu-Asp) and Epitalon (Ala-Glu-Asp-Gly): the AED tripeptide is identical to the N-terminal three residues of Epitalon, differing only by the absence of the C-terminal glycine. The two compounds are proposed to target different tissues — cartilage and pineal gland respectively — but whether the structural similarity between them has pharmacological implications has not been established through independent research.
2. Molecular Structure
Cartalax is a tripeptide with the sequence Ala-Glu-Asp, abbreviated in single-letter code as AED. At three residues and approximately 333 Da, it is among the smallest peptides in the research peptide catalogue. Two of its three residues (Glu and Asp) carry acidic side chains at physiological pH, giving the peptide a net negative charge of −2 under physiological conditions.
| Property | Detail |
|---|---|
| Sequence | Ala-Glu-Asp (AED) |
| Peptide length | 3 amino acids (tripeptide) |
| Molecular weight | ~333 Da |
| Net charge (pH 7.4) | −2 (Glu and Asp side chains ionized) |
| Related bioregulators | Epitalon (Ala-Glu-Asp-Gly); Pinealon (Glu-Asp-Arg) |
| Structural note | Identical to the N-terminal 3 residues of Epitalon; differs by absence of C-terminal Gly |
| Proposed tissue target | Cartilage / chondrocytes |
| Developer | Khavinson group, St. Petersburg Institute of Bioregulation and Gerontology |
3. Proposed Mechanisms
The proposed mechanisms of Cartalax follow the general bioregulator framework applied by the Khavinson group to the entire peptide class. Each proposed mechanism below remains incompletely characterized and has not been independently validated through research outside the originating group. The label “Proposed” in each card reflects this status.
4. Key Research Findings
4.1 In Vitro Chondrocyte Studies
Cell-based studies from the Khavinson group have examined Cartalax effects in chondrocyte culture models, reporting associations with parameters of cellular proliferation, matrix synthesis marker expression, and chondrocyte viability under stress conditions. These studies follow the methodology common to the broader bioregulator research program: exposure of cultured cells to the peptide followed by assessment of target gene or protein expression using standard molecular biology assays. Reported associations include modulation of markers related to extracellular matrix production, consistent with the proposed chondroprotective rationale for the compound.
As with other Khavinson peptide bioregulators, the in vitro data are derived from a single research group, have not been independently replicated in published form, and cannot be used to establish efficacy in a biological system more complex than the cell culture conditions in which they were produced. Cell culture studies also cannot account for pharmacokinetic factors — absorption, distribution, tissue penetration, metabolic clearance — that would determine whether the AED sequence reaches chondrocytes at biologically relevant concentrations following systemic administration.
4.2 Animal Model Studies
Animal model studies examining Cartalax effects on cartilage tissue parameters have been conducted within the Khavinson group’s broader bioregulator research program. These studies have generally employed rodent or other small animal models and examined histological or biochemical markers of cartilage tissue quality, matrix composition, and chondrocyte morphology. The published studies report directional associations consistent with the bioregulator hypothesis — reporting associations consistent with preservation or improvement in assessed parameters in Cartalax-treated animals relative to controls — though the mechanistic basis, dosing parameters, and generalizability of these findings across models remain incompletely characterized in accessible literature.
4.3 Structural Relationship to Epitalon — Class Context
The research context for Cartalax is informed in part by the larger body of literature on Epitalon (Ala-Glu-Asp-Gly), a tetrapeptide sharing the first three of Cartalax’s amino acids. Epitalon is among the more extensively published members of the Khavinson bioregulator class, with studies examining telomerase modulation, melatonin synthesis, and pineal gland-related endpoints. Anisimov and Khavinson (2010) reviewed the broader evidence base for peptide bioregulators across tissue targets, situating Cartalax within the cartilage-targeted arm of the program [2]. The structural proximity of AED (Cartalax) and AEDG (Epitalon) has not been used to mechanistically attribute Epitalon findings to Cartalax, and the two compounds are treated as distinct pharmacological entities with separate proposed tissue targets and evidence bases.
Qualitative representation of the relative volume and stage of available evidence for Cartalax. Bar lengths are schematic and do not represent quantitative study counts. All available research originates from the Khavinson group; independent replication has not been published as of the review date.
5. Evidence Status
| Proposed Effect / Claim | Current Status | Evidence Level |
|---|---|---|
| Gene promoter interaction (in silico) | Computational modeling from originating group; no independent experimental validation published | Limited |
| Chondrocyte activity modulation (in vitro) | Cell-based studies from originating group; not independently replicated in published literature | Limited |
| Cartilage tissue parameters (animal models) | Animal studies from originating group; limited accessible detail; not independently replicated | Limited |
| ECM protein synthesis modulation | Proposed from in vitro associations; mechanistic pathway not established independently | Limited |
| Anti-inflammatory effects (cartilage context) | Proposed from class-level framework; Cartalax-specific data not independently published | Limited |
| Efficacy or safety in humans (any indication) | No peer-reviewed randomized controlled trial identified as of the review date | Limited |
What We Still Don’t Know
- Human pharmacokinetics and bioavailability: How a tripeptide of 333 Da is absorbed following subcutaneous or other routes of administration, how rapidly it is degraded by plasma peptidases, and whether it reaches target tissues at concentrations relevant to the proposed mechanism have not been characterized in published human or animal pharmacokinetic studies for Cartalax specifically.
- Whether the proposed tissue-specificity is operative: The mechanism by which a freely circulating tripeptide would preferentially regulate gene expression in cartilage rather than liver, kidney, or other tissues encountered first has not been mechanistically explained or independently demonstrated. This is a fundamental unresolved question across the entire Khavinson bioregulator class.
- Dose-response relationships: The concentration of Cartalax required to produce the effects reported in cell culture studies, and whether these concentrations can be achieved in target tissues following systemic administration, has not been established in published research.
- Long-term effects and safety: No long-term preclinical toxicology studies or human safety data have been published for Cartalax. The effects of chronic exposure on cartilage tissue, systemic gene expression, or off-target tissue biology are unknown from published evidence.
- Independent replication of any finding: No study from a research group independent of the originating Khavinson laboratory has published findings specific to Cartalax in peer-reviewed form as of the review date, making it impossible to assess the reproducibility of the reported associations.
6. Limitations of Current Research
References
- Khavinson VKh, Morozov VG. “Peptides of pineal gland and thymus prolong human life.” Neuroendocrinology Letters. 2003;24(3–4):233–240.
- Anisimov VN, Khavinson VKh. “Peptide bioregulation of aging: results and prospects.” Biogerontology. 2010;11(2):139–149. doi:10.1007/s10522-009-9249-8
- Tarnovskaya SI, Khavinson VKh, Linkova NS, Pronyaeva VE, Kolchina NV, Tendler SM. “Mechanism of short peptides interaction with DNA.” Advances in Gerontology. 2014;27(4):706–714.
- Bhosale AM, Richardson JB. “Articular cartilage: structure, injuries and review of management.” British Medical Bulletin. 2008;87:77–95. doi:10.1093/bmb/ldm035
- Goldring MB. “The role of the chondrocyte in osteoarthritis.” Arthritis & Rheumatism. 2000;43(9):1916–1926. doi:10.1002/1529-0131(200009)43:9<1916::AID-ANR2>3.0.CO;2-I